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infusion (2 days). Regarding the proportions of circulating 
CD4+ T lymphocytes, only a reduction in the frequencies of 
circulating Treg cells was observed.  Conclusions: Abatacept 
in vitro inhibits proliferation and cytokine production in 
healthy donors, and reduces parameters of inflammation in 
vivo in JIA patients. The reduction of the proliferative re-
sponse to recall antigens induced by abatacept was evident 
only soon after drug administration, suggesting that its im-
munosuppressive activity is maintained only for a short
time.  © 2016 S. Karger AG, Basel 
 Introduction 
 Juvenile idiopathic arthritis (JIA) is the most common 
form of persistent arthritis in children. The cause of the 
disease is unknown  [1] , but in its pathogenesis the adap-
tive immune response is certainly involved, as indicated 
by the presence of T and B lymphocytes infiltrating the 
synovial membrane of inflamed joints  [2] . CD4+CD161+ 
T helper (Th) cells are enriched in the inflamed joints 
with respect to peripheral blood (PB), and they belong to 
either the Th1, Th17, or Th17/Th1 subset  [3] . In particu-
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 Abstract 
 Background: Abatacept is used in the treatment of juvenile 
idiopathic arthritis (JIA) patients, but the activity of the drug 
on T helper cell function is not yet fully known.  Methods: 
The ability of abatacept to affect cytokine production in vitro 
and the proliferative response to both recall antigens and 
polyclonal stimulation was firstly assessed in healthy donors. 
Then, 10 JIA patients who were due to start abatacept treat-
ment were recruited and longitudinally evaluated during 
the first 90 days of therapy. Both their clinical response to the 
treatment and in vitro analysis aimed to assess the prolif-
erative response to recall antigens and the proportions of 
circulating T helper subsets.  Results: Abatacept reduced the 
proliferative response to recall antigens and the production 
of proinflammatory cytokines such as IFN-γ and TNF-α in 
healthy donors in vitro. It was also efficient in improving 
symptoms and reducing parameters of inflammation in JIA 
patients. Abatacept reduced the proliferative response to re-
call antigens, and this effect was significant soon after drug 
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lar, the proportions of Th17/Th1 lymphocytes in the sy-
novial fluid of inflamed joints positively correlated with 
parameters of disease activity, such as the erythrocyte 
sedimentation rate (ESR) and levels of C-reactive protein 
(CRP), in oligoarticular JIA  [4] .
 Pharmacologic therapy in JIA is essentially based on 
the use of nonsteroidal anti-inflammatory drugs and 
disease-modifying antirheumatic drugs (DMARDs)  [1] . 
Among both biologic and nonbiologic DMARDs, meth-
otrexate, thanks to clinical benefits with an acceptable 
profile of toxic effects, is considered the standard first-
line treatment  [5] . Some patients, in particular those 
with the polyarticular subset of JIA, could have a subop-
timal response to nonbiologic DMARDs, becoming can-
didates to receive biologic agents. The use of biologics 
has resulted in an improvement in the treatment of JIA, 
permitting disease control in patients refractory to the 
pharmacological agents previously available. Among bi-
ologics, etanercept, infliximab, and adalimumab act by 
blocking TNF-α (tumor necrosis factor-α), thereby pre-
venting its proinflammatory actions. Other biologics 
used to treat JIA include interleukin-1 blockers (anakin-
ra, canakinumab, and rilonacept), the interleukin-6 
blocker tocilizumab, CD20/B cell-targeted rituximab 
and the T cell costimulatory signal blocker abatacept. 
Abatacept is a chimeric CTLA4 and IgG Fc fusion pro-
tein that inhibits the CD80/CD86-CD28 costimulatory 
signal required for full T cell activation  [6] . Through its 
CTLA4 portion, abatacept binds to CD80 and CD86 on 
APCs (antigen-presenting cells), thereby inhibiting 
CD28 costimulation. CD28-mediated signals are rele-
vant in the upregulation of CD154 (the ligand for CD40) 
on the T cell surface, a key process in the acquisition of 
the T cell ‘helper’ function. Consequently, in patients 
with rheumatoid arthritis (RA), abatacept has been 
shown to be able to reduce signs of polyclonal B cell ac-
tivation, inducing a trend toward the normalization of 
serum levels of different classes of Ig, decreasing titers of 
anti-citrullinated protein antibodies and rheumatoid 
factor, and percentages of post-switch memory B cells 
 [7] . The safety, tolerability, and clinical efficacy of aba-
tacept in children and adolescents with JIA have been 
demonstrated in a double-blind, placebo-controlled, 
randomized withdrawal trial  [8] . Recently, by compar-
ing the efficacy of different biologics in the polyarticular 
course of JIA, it has been reported that the short-term 
efficacy of etanercept, adalimumab, and abatacept is 
similar  [9] . In this study we evaluated the ability of aba-
tacept to influence Th functions in JIA patients, both in 
vitro and ex vivo.
 Materials and Methods 
 Subjects 
 PB samples for the in vitro study were obtained from 7 healthy 
donors and from 10 JIA patients whose diagnosis was made in ac-
cordance with the International League of Associations for Rheu-
matology classification criteria for JIA  [10] . The patients’ demo-
graphic and clinical characteristics are presented in  Table 1 . The 
reason for introducing abatacept was mostly persistent arthritis, 
but the presence of refractory uveitis (especially in oligoarticular 
disease) was also a factor. Corticosteroids, when administered, 
were always given at low doses (prednisone <10 mg/day), which 
were maintained stable during the study period. Abatacept was 
administered intravenously with the usual protocol of 10 mg/kg at 
time zero (T0; half dose), 15 and 30 days, and monthly thereafter. 
At each administration a full general and articular examination 
was performed. The ESR (normal values up to 30 mm/h) and the 
CRP serum levels (normal values up to 0.3 mg/dL; assessed using 
the particle-enhanced turbidimetric immunoassay method) were 
evaluated by staff in the service laboratory of the Anna Meyer Pe-
diatric Hospital in Florence, Italy.
 The procedures followed in the study were in accordance with 
the ethics standards of the Regional Committee on Human Ex-
perimentation. Informed consent was obtained from parents or 
guardians.
 PB samples from JIA patients were obtained before the begin-
ning of abatacept treatment (T0) and at time points 2, 15, 17, 30, 
32, 60, 62, 90, and 92 days after the beginning of abatacept treat-
ment, representing each time of abatacept administration (before 
drug infusion), and 2 days later.
 Reagents 
 The medium used for cultures was RPMI 1640 (Merck Milli-
pore), supplemented with 2 m M  L -glutamine, 1% nonessential 
amino acids, 1% sodium pyruvate, 2 × 10 –5  M 2-mercaptoethanol 
(all from Sigma), and 5% autologous serum for JIA patients or 5% 
AB serum (Lonza Ltd.) for healthy donors. Fluorochrome-conju-
gated monoclonal antibodies (mAbs) were from BD Biosciences 
(anti-CD3, CD4, CD8, CD161, IFN-γ, TNF-α, IL-4, IL-10) or from 
eBiosciences (anti-IL-17). Lymphoprep (Fresenius Kabi Norge) 
 Table 1.  Patients’ demographic and clinical characteristics
Patient 
No.
Sex Age, 
years
Diagnosis Therapy (in addition
to abatacept)
1 F 13 Polyarticular JIA Steroids
2 F 14 Oligoarticular JIA Methotrexate
3 F 12 Polyarticular JIA Steroids
4 M 11 Oligoarticular JIA Methotrexate
5 F 13 Oligoarticular JIA Steroids, methotrexate
6 F 13 Polyarticular JIA Steroids, methotrexate
7 F 14 Polyarticular JIA Steroids
8 F 11 Oligoarticular JIA Steroids
9 F 9 Oligoarticular JIA Steroids, methotrexate
10 F 14 Polyarticular JIA Methotrexate
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was used to obtain MNCs (mononuclear cells) by density gradient 
stratification from the PB of healthy donors and JIA patients.
 Abatacept for the in vitro part of the study was provided by 
Bristol-Myers Squibb. Drug powder was dissolved in deionized 
water at a concentration of 250 mg/mL and then dialyzed in an ap-
propriate tube (dialysis/Visking tubing, diameter 6.3 mm; Medi-
cell International Ltd) versus deionized water. The final formula-
tion was aliquoted and stored at –20  °  C.
 Proliferation Assay 
 10 5 MNCs from the PB of healthy donors and JIA patients were 
stimulated in triplicate on 96 U-bottomed plates (Nunc, Sigma Al-
drich) with anti-CD3 plus anti-CD28 mAbs (BD Biosciences, 5 μg/
mL each) and IL-2 (25 U/mL; Proleukin, Novartis), or anti-CD3 
and IL-2 (25 U/mL), or tetanus toxoid (TT; 10 μg/mL), or strepto-
kinase (SK; 5,000 U/mL), in the presence or absence of abatacept 
(ranging from 1 to 10 μg/mL). On day 5, T cell culture supernatants 
were recovered in order to evaluate IL-2, IL-4, IL-10, IL-17, TNF-α, 
and IFN-γ levels by using BD Biosciences Cytometric Bead Array 
(CBA), whereas cells were pulsed for 16 h with 0.5 μCi of  3 H-TdR 
(Perkin Elmer) and harvested. Then, radionuclide uptake was 
measured by a β-counter in the presence of scintillation buffer.
 Intracellular Cytokines Detection 
 PBMCs from patients with JIA were analyzed by flow cytom-
etry, using a BD Biosciences LSR II instrument and Diva soft-
ware, to assess the production of intracellular cytokines and ex-
pression of surface molecules, as previously described  [4] . Brief-
ly, freshly isolated PBMCs were stimulated with phorbol myristate 
acetate (PMA) plus ionomycin (Sigma) for 6 h, with the last 4 h 
in the presence of Brefeldin A (Sigma) as a Golgi inhibitor. The 
cells were then fixed in 2% formaldehyde (Sigma), permeabilized 
with 0.5% saponin (Sigma) and stained with the following fluo-
rochrome-conjugated mAbs: anti-CD3, CD4, CD8, CD161, 
IFN-γ, TNF-α, IL-4, IL-10, and IL-17. The gating strategy was as 
follows. PBMCs were first analyzed for their distribution in a 
FSC/SSC dot plot and the lymphocyte region was selected, ex-
cluding monocytes. The lymphocytes were then analyzed for 
CD3 expression (in a dot plot FSC/CD3) and CD3+ cells were 
gated in a CD4/CD8 dot plot to select CD3+CD4+ T cells. Then, 
this latter population was analyzed for intracellular markers in 
association with CD161.
 Treg Cells Evaluation 
 To determinate the frequency of Treg cells, a human Foxp3 
staining set was used (eBioscience) following the manufacturer’s 
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 Fig. 1. Abatacept in vitro inhibits T cell proliferation and TNF-α 
production in PBMCs from healthy donors.  a Columns represent 
mean values (±SE) of proliferative response to TT (white bars), SK 
(gray bars), and polyclonal stimulation with anti-CD3 plus IL-2 
(black bars), in the absence (medium) or presence of different 
abatacept doses in PBMCs obtained from 7 healthy donors.  b Col-
umns represent mean values (±SE) of cytokine levels in culture 
supernatants of the anti-CD3 plus IL-2 cultures in the same do-
nors, in the absence or presence of abatacept.  *   p < 0.05, presence 
of abatacept versus medium of each culture condition. 
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instructions. Briefly, PBMCs from JIA patients were fixed with fix-
ation/permeabilization buffer diluted 1: 4, then they were permea-
bilized in the presence of 1× permeabilization buffer and stained 
with the following fluorochrome-conjugated mAbs: anti-CD3, 
CD4, CD25, and anti-Foxp3 (PCH101). Finally, the cells were an-
alyzed by flow cytometry LSR II and the gating strategy was as fol-
lows. PBMCs were first analyzed for their distribution in a FSC/
SSC dot plot and the lymphocyte region was selected, excluding 
monocytes. Then lymphocytes were analyzed for CD3 and CD4 
expression (in a dot plot CD3/CD4) and CD3+CD4+ cells were 
selected and evaluated in a CD25/Fopx3 dot plot.
 Statistical Analysis 
 A standard 2-tailed paired  t test was used for statistical analysis. 
 p values  ≤ 0.05 were considered significant.
 Results 
 Abatacept Inhibits Recall Antigen-Induced T Cell 
Proliferation and the Production of Proinflammatory 
Cytokines in vitro 
 PBMCs from 7 healthy donors were evaluated in vitro 
for their proliferative response to both polyclonal and re-
call antigen stimulation in the absence or presence of 
abatacept. The inhibition of the proliferative response in 
the TT-induced proliferation was significant, starting 
from the lowest dose of abatacept (1 μg/mL), whereas in 
the SK-induced proliferation it became evident at a con-
centration of 5 μg/mL. The proliferative response to CD3 
stimulation was clearly inhibited from the lowest dose 
( Fig. 1 a). Of note, CD3/CD28-stimulated samples were 
only slightly inhibited at the highest dose (10 μg/mL) of 
abatacept (data not shown).
 Cytokines were detected in the supernatants of prolif-
eration wells. The levels of IL-2, IL-4, IL-17, and IL-10 
were low or undetectable in all of the samples (data not 
shown), whereas IFN-γ and TNF-α, even if undetectable 
in the TT cultures, were appreciable in both SK (data not 
shown) and CD3-stimulated cultures. In these latter, we 
found a significant reduction of these cytokines in the 
presence of abatacept ( Fig. 1 b).
 Abatacept in JIA Patients Reduces Parameters of 
Disease Activity 
 Once the capacity of abatacept to suppress the in vitro 
proliferative response and the production of cytokines in 
PBMCs from healthy donors was established, we evalu-
ated the effect of the drug in a group of 10 JIA patients, 
both before and during abatacept treatment. These pa-
tients were unresponsive to conventional treatment and 
their main features are reported in  Table 1 .
 The clinical response was evaluated in these patients 
by looking at the number of involved joints after 15, 30, 
60, and 90 days of abatacept treatment. Moreover, serum 
parameters of inflammation, such as ESR and CRP, were 
also evaluated. Both the number of inflamed joints 
( Fig. 2 a) and ESR ( Fig. 2 b) were significantly reduced af-
ter 60 days of abatacept treatment, with this effect being 
maintained at least until day 90, whereas only a trend to 
reduction without significance was observed in the CRP 
levels ( Fig. 2 c). Flares of uveitis tended to decrease, but 
0
In
fla
m
ed
 jo
in
ts
, n
6
5
4
3
2
1
0
15 30
Time, daysa
60
*
90
*
0
ES
R,
 m
m
/h
60
50
40
30
20
10
0
15 30
Time, daysb
60
*
90
*
0
CR
P, 
m
g/
dl
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
15 30
Time, daysc
60 90
 Fig. 2. Treatment with abatacept reduces the number of inflamed 
joints and serological parameters of inflammation. Columns rep-
resent the mean values (±SE) of the number of inflamed joints ( a ), 
of the ESR ( b ), and of the CRP serum levels ( c ) in 10 JIA patients 
at different time points after commencing abatacept treatment.
 *   p < 0.05, each time point versus T0. 
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the relative short follow-up and small numbers precluded 
statistical comparisons (data not shown).
 Abatacept Inhibits TT-Induced Proliferation Soon 
after Its Administration 
 Once the efficacy of abatacept to improve symptoms 
and serum parameters of inflammation in JIA was estab-
lished, we proceeded to assess the ability of the drug to 
inhibit the in vitro proliferative response to TT. We com-
pared the in vitro proliferative response to TT stimulation 
before the beginning of the treatment (T0) with the re-
sponses after 15, 30, 60, and 90 days of treatment, finding 
only a nonsignificant trend of reduction ( Fig.  3 a). We 
then wondered if this lack of appreciable effects was due 
to the fact that we checked proliferative responses at a 
long time interval after drug administration. To answer 
this question, we compared the proliferative responses to 
TT stimulation on days 15, 30, 60, and 90 (15 or 30 days 
after abatacept administration) with those on days 2, 17, 
32, 62, and 92 (2 days after abatacept administration). As 
shown in  Figure 3 b and c, TT-specific proliferation was 
constantly reduced soon after abatacept administration. 
Indeed, the mean of the proliferative response obtained 2 
days after drug administration (i.e. time 2, 17, 32, 62, and 
92) was significantly lower than that obtained at a longer 
interval from drug administration (i.e. time 0, 15, 30, 60, 
and 90 days;  Fig. 3 b).
 Abatacept Activity on the Proportions of Circulating 
CD4+ T Helper Subsets 
 Since we recently showed the ability of etanercept to 
reduce the proportions of CD4+CD161+ (nonclassic) 
Th1 lymphocytes in the PB of JIA patients  [11] , we won-
dered if abatacept had a similar behavior. However, we 
did not find any variation in the frequency of circulating 
Th1 (classic and nonclassic), Th17, and Th17/Th1 subsets 
( Fig. 4 a), or of Th2 lymphocytes (data not shown). Sim-
ilarly, we assessed the ability of PBMC-derived CD4+
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 Fig. 3. Treatment with abatacept reduces the in vitro proliferative 
response to TT soon after drug administration.  a Columns repre-
sent mean values (±SE) of proliferative response to TT at different 
time points after commencing abatacept treatment.  b Columns 
represent mean values (±SE) of proliferative response to TT at dif-
ferent times after commencing abatacept treatment in PBMCs ob-
tained from the 10 JIA patients. White bars indicate the value ob-
tained just before drug infusion and black bars the value obtained 
2 days later.  *   p < 0.05.  c Proliferative response to TT of PBMCs in 
each patient at T0 and after 2 days of abatacept treatment. 
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T lymphocytes to produce a panel of several cytokines 
(IL-4, IL-10, TNF-α) after in vitro stimulation with PMA 
plus ionomycin, and again did not find any variation dur-
ing the period of treatment ( fig. 4 b). Moreover, we found 
a decrease, at least in terms of frequency, of the regula-
tory CD4+CD25+Foxp3+ subset, which was reduced 
from 15 days after starting the treatment until day 90 of 
observation ( fig. 4 c).
 Discussion 
 The activation of T cells involves 2 major steps, the 
presentation of a peptide by an APC to the T cell receptor, 
and the signal derived from costimulatory molecules, the 
most important being the interaction between CD80/
CD86 and CD28. The molecules CD80/CD86 were ex-
pressed by APCs, whereas CD28 were expressed by T 
cells. In particular, virtually all T cells (both naïve and 
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 Fig. 4. Treatment with abatacept reduces the frequencies of circu-
lating CD4+CD25+Foxp3+ in JIA patients.  a One example of the 
gating strategy for distinguishing such Th subsets is depicted. Col-
umns represent mean values (±SE) of the frequencies of Th17 
(white bars), Th17/Th1 (grey bars), nonclassic Th1 (black bars), 
and classic Th1 (dashed bars), subsets, based on their IL-17, IFN-γ, 
and CD161 expression after in vitro polyclonal stimulation with 
PMA plus ionomycin, in PB CD4+ T cells of 10 JIA patients, at dif-
ferent time points after commencing abatacept treatment.  b Col-
umns represent mean values (±SE) of the frequencies of IL-4- 
(white bars), IL-10- (grey bars), and TNF-α- (black bars) produc-
ing Th cells after in vitro polyclonal stimulation with PMA plus 
ionomycin, in PB CD4+ T cells of the same 10 JIA patients at
different time points after commencing abatacept treatment.
 c Columns represent mean values (±SE) of the frequencies of
the Tregs (CD4+CD25+Foxp3+, black bars) and the T effector 
(CD4+CD25+Foxp3–, white bars) subsets in PB of the same pa-
tients. Plots (right) are of 1 representative patient at T0 and 90 
days.  *   p < 0.05, each time point versus T0. 
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memory) express CD28, even if in the elderly a subset of 
memory T cells may become CD28 negative as a result of 
repetitive cell divisions, the influence of TNF-α, or infec-
tions  [12] . CTLA-4 (CD152) is a member of the CD28 
immunoglobulin superfamily expressed on the T cell 
membrane. It has a structural resemblance to CD28, but 
its affinity to CD80/CD86 is much higher. CD28 trans-
mits a stimulatory effect, enhancing the activation and 
upregulation of downstream pathways, whereas CTLA-4 
transmits an inhibitory signal to T cells, inducing aner-
gy  [13] . The absence of the ITIM motif in CTLA-4 has 
suggested the hypothesis that the function of CTLA-4 cy-
toplasmic domain is not to transmit inhibitory signals
but to precisely control the turnover, cellular location, 
and membrane delivery of CTLA-4 to facilitate its cen-
tral function, i.e. regulating the access of CD28 to their 
shared ligands  [14] .
 In this study we evaluated the capacity of abatacept, a 
soluble chimeric CTLA4 protein, which binds with high 
affinity to the B7 molecules CD80 and CD86 limiting the 
activation and reactivation of CD4+ T cells via CD28, to 
suppress Th functions such as antigen-specific prolifera-
tion and cytokine production, both in vitro in healthy 
subjects and ex vivo in a group of abatacept-treated JIA 
patients. First of all, we checked the ability of abatacept to 
inhibit T cell proliferation in vitro in response to antigen-
specific and polyclonal stimulation. Abatacept was able to 
inhibit the TT-specific and the SK-specific proliferation, 
as well as the proliferative response induced by CD3-spe-
cific mAb. As expected, when the blocking activity of the 
drug was bypassed by the CD3/CD28 stimulation, the in-
hibitory effect was not evident. These data substantially 
reflect the mechanism of action of the drug. In fact, 
through binding to CD80/CD86, abatacept selectively 
impairs the costimulation of T cells exerted by APCs. In 
the same model, we also checked the levels of cytokines 
in the culture supernatants. Among the cytokines evalu-
ated IFN-γ and TNF-α were detectable in both SK and 
polyclonal stimulations. Both these proinflammatory cy-
tokines were significantly reduced in the presence of 
abatacept only in the CD3-stimulated samples. These 
proinflammatory cytokines, and particularly TNF-α, cer-
tainly play a crucial role in the triggering and in the main-
tenance of joint inflammation. Collectively, these in vitro 
data confirm the capacity of abatacept to impair the in 
vitro T cell proliferation  [15] and TNF-α production, the 
role of which in joint inflammation in JIA is well estab-
lished  [16] .
 In the second part of the study, we longitudinally eval-
uated 10 JIA patients undergoing abatacept treatment. 
Patients were checked for clinical parameters, such as the 
number of involved joints and serum parameters of in-
flammation, and for in vitro functional features, such as 
the ability to proliferate and to produce cytokines in re-
sponse to different stimuli, and the distribution of differ-
ent Th subsets in PB. The evaluations were performed at 
T0, 2, 15, 17, 30, 32, 60, 62, 90, and 92 days, with the aim 
of assessing if the in vitro functions were affected soon 
after drug administration or if the effects were main-
tained until the following infusion.
 Despite the relatively low number of recruited pa-
tients, the clinical efficacy of abatacept was evident after 
just 60 days, when we started to observe a reduction in the 
number of involved joints and of ESR. This was main-
tained at least until 90 days of treatment, in agreement 
with previous data obtained in RA patients  [17] . Con-
cerning the proliferative response to TT stimulation, 
PBMCs from JIA patients showed no differences between 
T0 and 90 days. These data are in contrast to those re-
ported by Pieper et al.  [18] , and also with our observation 
that the exogenously added abatacept in vitro is able to 
inhibit both the proliferation and cytokine production in 
PBMCs of healthy donors. Interestingly, when we looked 
at TT-induced proliferation soon after abatacept admin-
istration we found a significant reduction. Of note, this 
reduction reflects the data obtained in the in vitro model 
of exogenously added abatacept. This finding led us to 
speculate that the activity of abatacept could progressive-
ly decrease after its administration.
 Regarding the ex vivo assessment, we found no modi-
fication in the frequencies of circulating Th1, both classic 
and nonclassic, Th17, and Th17/Th1 subsets during the 
first 90 days of treatment. Of note, we recently reported 
that etanercept in JIA patients was able to reduce the fre-
quencies of circulating nonclassic Th1 cells and to en-
hance the frequencies of Th17 cells by inhibiting the 
TNF-α-driven shift of Th17 lymphocytes toward a non-
classic Th1 phenotype  [11] . Also, the frequencies of cells 
able to produce other cytokines (IL-4, IL-10, and TNF-α) 
were unaltered during the first 90 days of treatment. 
Moreover, the analysis of JIA patients subgrouped on the 
basis of diagnosis (5 oligoarticular and 5 polyarticular 
JIA) did not reveal any difference in Th cell phenotype 
during this time. Interestingly, the only subset that was 
modified by the therapy was the regulatory one. In par-
ticular, we found a significant reduction in the frequen-
cies of the CD4+CD25+Foxp3+ subset, in agreement 
with Pieper et al.  [18] . A possible explanation for this re-
duction could be that abatacept, by binding with CD80/
CD86, is able to prevent the interaction not only with 
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CD28, but also with CTLA-4, which has been shown to 
be highly expressed on CD4+CD25+ Tregs  [19] . More-
over, other papers demonstrated that the reduction of 
Treg cells after CTLA4-Ig treatment could depend on the 
lack of a CD28 costimulation signal  [20] as well as on the 
reduction of IL-2, which is necessary for Treg expansion 
 [21] . However, it has been clearly shown in RA that this 
reduction of the frequencies of Treg is not associated with 
a decrease, but rather with an enhancement of their ac-
tivity  [22–23] .
 Collectively, our data confirm that abatacept is useful 
in ameliorating JIA in subjects with an inadequate re-
sponse to other DMARDs, including biologics  [24–25] . 
Moreover, we provided evidence that abatacept impaired 
some Th functions, such as the in vitro proliferative re-
sponse to recall antigens, and the ability to produce cyto-
kines. To our knowledge, this is the first report indicating 
that such effects are evident only when abatacept levels 
are expected to be highest (soon after its administration). 
Finally, further studies are needed to investigate if the
reduction of the intervals among drug administration 
could be of help for optimizing the immunosuppressive 
activity exerted by abatacept.
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